Mount Sinai Health System · 10 hours ago
Postdoctoral Fellow-MSH-12907-048
Maximize your interview chances
Health CareHospital
Actively Hiring
Insider Connection @Mount Sinai Health System
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Designing and executing studies with human samples and experimental models
Unravel the molecular determinants of liver cancer onset and progression
Identify novel treatments for hepatocellular carcinoma (HCC) patients
Discover predictors of response to molecular and immune therapies
Analysis of the tumor microenvironment of HCC by applying cutting edge technologies such as single cell sequencing
Generation of novel animal models of the disease
Therapeutic targets discovery in sophisticated in vitro systems
Mapping of the immune cell microenvironment in human HCC related to non-alcoholic steatohepatitis (NASH)
Identification of biomarkers of response to treatments (including immune checkpoint inhibitors and combinations)
Development of mouse models and innovative preclinical models that recapitulate specific NASH-HCC features to test the efficacy of novel therapies and assess their mechanisms of action
Supervision and mentoring of PhD students
Project coordination
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
PhD in a research field related to cancer translational medicine
Advanced level in written and spoken English
Proven track record of first-author publications
Hardworking and motivated
Experience in cancer research
Stays abroad (>1 year), preferably in worldwide recognized scientific institutions.
Preferred
Experience in cancer molecular biology
Experience in cancer genomics
Experience in immunology
Experience in animal modeling of cancer
Experience in bioinformatics
Benefits
Subsidized housing
Health insurance
Company
Mount Sinai Health System
Mount Sinai Health System delivers integrated medical care, research, and medical education through its network.
Funding
Current Stage
Late StageTotal Funding
$41.9MKey Investors
National Institutes of HealthHearst Health Prize.Multiple Myeloma Research Foundation
2024-11-11Grant· $7M
2024-06-06Grant· $0.1M
2023-11-02Grant· $7M
Leadership Team
Recent News
EIN Presswire
2024-12-03
Company data provided by crunchbase